Search
Bivalirudin
go.drugbank.com/drugs/DB00006ApprovedInvestigationalBivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is a...
Estrone sulfate
go.drugbank.com/drugs/DB04574ApprovedEstrone sulfate (as estropipate) is a form of estrogen. It has several uses such as: alleviate symptoms of menopause as hormone replacement therapy, treatment some types of infertility, treatment of some conditions leading to underdevelo...
Relebactam
go.drugbank.com/drugs/DB12377ApprovedInvestigationalRelebactam is a diazabicyclooctane beta-lactamase inhibitor, similar in structure to avibactam. It includes a piperidine ring which reduces export from bacterial cells by producing a positive charge. It is currently available in a combin...
Toremifene
go.drugbank.com/drugs/DB00539ApprovedInvestigationalToremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like tamoxifen, toremifene is part of the first-generation triphenylethylene derivative ...
Mixtures: FLOBACT - D, FLOBACT - DFlumethasone
go.drugbank.com/drugs/DB00663ApprovedVet approvedFlumethasone is a moderately potent difluorinated corticosteroid ester with anti-inflammatory, antipruritic and vasoconstrictive properties. As it is a privalate salt, its anti-inflammatory action is concentrated at the site of applicati...
Zalcitabine
go.drugbank.com/drugs/DB00943ApprovedWithdrawnA dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of 5' to 3' phosphodiester linkages, which are needed for the elongation of DNA cha...
Ecallantide
go.drugbank.com/drugs/DB05311ApprovedApart from its FDA and EMA indication, ecallantide has been used off label in the management of nonhistaminergic angioedema, not due to HAE [A32017].
DAR-0100A
go.drugbank.com/drugs/DB16139InvestigationalDAR-0100A is under investigation in clinical trial NCT01466205 (Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder).
Categories: Dopamine D1 Receptor AgonistsIMM-101
go.drugbank.com/drugs/DB15850InvestigationalAs of July 2020, researchers from the Ottawa Hospital and Queen’s University, in partnership with the Canadian Cancer Society-funded Canadian Cancer Trials Group (CCTG), are conducting a trial in over
Pomalidomide
go.drugbank.com/drugs/DB08910ApprovedInvestigationalPomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.